Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ARQT · as of Sep 30, 2025
Ownership Breakdown
250
Institutional Holders
▲ 12 vs Q2
$2.37B
Total Inst. Value
▲ $597.96M vs Q2
125.08M
Shares Outstanding
freeFloat 88.28%
125.82M
13F Shares Held
▼ 710,621 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ARQT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
JENNISON ASSOCIATES LLC pharmaceutical preparations | 12.25M | 9.65% | 9.65% | $230.99B | Oct 30, 2025 | ▲ 1.14M |
RUBRIC CAPITAL MANAGEMENT LP pharmaceutical preparations | 10.75M | 8.46% | 8.46% | $202.63B | Nov 14, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 10.48M | 8.25% | 8.25% | $197.51B | Nov 14, 2025 | ▼ 1.06M |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. pharmaceutical preparations | 9.87M | 7.78% | 7.78% | $186.13B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 8.57M | 6.75% | 6.75% | $161.62B | Nov 12, 2025 | ▲ 41.2K |
VANGUARD GROUP INC pharmaceutical preparations | 7.15M | 5.63% | 5.63% | $134.70B | Nov 7, 2025 | ▲ 97.0K |
POLAR CAPITAL HOLDINGS PLC pharmaceutical preparations | 5.30M | 4.17% | 4.17% | $99.88B | Nov 14, 2025 | ▲ 292.3K |
STATE STREET CORP pharmaceutical preparations | 4.64M | 3.65% | 3.65% | $87.49B | Nov 14, 2025 | ▲ 114.4K |
GILDER GAGNON HOWE & CO LLC pharmaceutical preparations | 4.43M | 3.49% | 3.49% | $83.49B | Nov 14, 2025 | ▲ 273.3K |
MORGAN STANLEY pharmaceutical preparations | 4.28M | 3.37% | 3.37% | $80.61B | May 27, 2026 | ▼ 38.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+7.20M shares1
New Positions
first time holders19
Decreased
−4.36M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.84M
+7.20M / −4.36M
Net new holders
+8
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ARQT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
9
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Vairavan Latha SVP Chief Financial Officer | May 11, 2026 | Sale | 435 | $21.05 | $9.2K | 86.0K | Form 4 ↗ |
Burnett Patrick See Remarks | May 11, 2026 | Sale | 222 | $21.05 | $4.7K | 120.2K | Form 4 ↗ |
Matsuda Masaru See Remarks | May 4, 2026 | Sale | 7,372 | $23.27 | $171.5K | 127.6K | Form 4 ↗ |
Matsuda Masaru See Remarks | May 4, 2026 | Sale | 884 | $23.61 | $20.9K | 126.7K | Form 4 ↗ |
Burnett Patrick See Remarks | May 4, 2026 | Sale | 684 | $23.61 | $16.1K | 120.5K | Form 4 ↗ |
Vairavan Latha SVP Chief Financial Officer | May 4, 2026 | Sale | 1,341 | $23.61 | $31.7K | 86.4K | Form 4 ↗ |
Watanabe Todd See Remarks | May 4, 2026 | Sale | 3,172 | $23.61 | $74.9K | 720.8K | Form 4 ↗ |
Welgus Howard G. director | May 1, 2026 | Sale | 7,144 | $22.99 | $164.2K | 32.6K | Form 4 ↗ |
Welgus Howard G. director | Apr 1, 2026 | Sale | 10,000 | $23.88 | $238.8K | 39.7K | Form 4 ↗ |
Leonard Keith R director | Mar 2, 2026 | Sale | 39,272 | $25.39 | $997.2K | 22.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Arcutis Biotherapeutics, Inc. (ARQT) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 11.72%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Arcutis Biotherapeutics, Inc. is JENNISON ASSOCIATES LLC, holding approximately 12.25 million shares — equal to 9.65% of outstanding shares — as of September 30, 2025.
A total of 250 institutional investors currently hold ARQT stock, with a combined institutional value of approximately $2.37 billion as of the most recent 13F filing period.
Frequently asked questions
ARQT ownershipArcutis Biotherapeutics, Inc. (ARQT) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is JENNISON ASSOCIATES LLC with a 9.65% stake. Company insiders hold 11.72%. Data sourced from SEC Form 13F as of September 30, 2025.